| 36.4 -0.453 (-1.23%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 43.74  |
1-year : | 46.3 |
| Resists | First : | 37.45 |
Second : | 39.64 |
| Pivot price | 37.51  |
|||
| Supports | First : | 33.9 |
Second : | 28.2 |
| MAs | MA(5) : | 37.6 |
MA(20) : | 36.77 |
| MA(100) : | 31.55 |
MA(250) : | 0 | |
| MACD | MACD : | 0.8 |
Signal : | 1 |
| %K %D | K(14,3) : | 49.6 |
D(3) : | 68.8 |
| RSI | RSI(14): 49.7 |
|||
| 52-week | High : | 39.64 | Low : | 23.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ GNMX ] has closed above bottom band by 15.6%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 37.05 - 37.26 | 37.26 - 37.49 |
| Low: | 35.49 - 35.72 | 35.72 - 35.98 |
| Close: | 35.96 - 36.37 | 36.37 - 36.81 |
GNMXtargets pure-play or the top 10 companies materially involved ingenomics and precision medicine, including those focused on gene sequencing, molecular diagnostics, gene editing and therapy, targeted treatments, and related healthcare technologies.The fund considers companies deriving significant revenue from this theme, spanningthose thatsupport personalized medicine through bioinformatics, clinical data platforms, laboratory tools, and services that improve disease detection, patient stratification, and treatment development.Using a bottom-up approach that combines fundamental analysis with thematic and quantitative screening, the fund invests in US and international stocks of any market capitalization. Otherfactors include supply chain positioning, growth potential, and valuation. Up to 15% may beallocatedto illiquid investments, including passive minority interests in SPVs. Holdings may include cash, cash equivalents, or short-term US treasuries for liquidity or portfolio management.
Mon, 05 Oct 2026
Corgi Coffee & Energy Drinks ETF (BREW) stock price, news, quote and history - Yahoo Finance Australia
Thu, 24 Sep 2026
Best Performing ETFs: Top Returns at a Glance - TradingKey
Thu, 04 Jun 2026
Corgi Lithography & Semiconductor Photonics ETF (EUV) Holdings - Yahoo! Finance Canada
Wed, 13 May 2026
The 5 Thematic ETFs Beating the S&P 500 — and 388 That Aren't - ETF.com
Sun, 10 May 2026
Corgi Drones & Urban Air Mobility ETF (BZZ) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wed, 06 May 2026
Corgi Launches 34 ETFs & Raises $160M in a Single Day - ETF.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
CBOE
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|